Home>Publications>Patient interviews in TELESTAR, a phase 3 study of telotristat etiprate, report meaningful improvement in carcinoid syndrome
Pavel M, Horsch D, Anthony L, Ervin C, Kulke MH, Bergsland E, Caplin M, Oberg K, Warner R, Kunz P, Metz DC, Pasieka J, Pavlakis N, DiBenedetti D, Lapuerta P. Patient interviews in TELESTAR, a phase 3 study of telotristat etiprate, report meaningful improvement in carcinoid syndrome. Poster presented at the 2016 European Neuroendocrine Tumor Society (ENETS) Annual Meeting; March 2016. Barcelona, Spain. [abstract] Neuroendocrinology. 2016; 103:89.
The power of knowledge. The value of understanding.
Steeped in a tradition of rigor and process, we maintain a legacy of setting the scientific standards within our industry. We employ the right approaches and proven research practices to analyze evidence and draw meaningful insights. Our uncompromisingly ethical and objective researchers ensure that results will hold up to scrutiny and reveal the benefits, risks, value and potential of your products. Learn more.